Together we advance PR600
03. January 2022
Investigational New Drug Application for PR600 expected in 3Q 2022.
Prometheus Biosciences and Dr. Falk Pharma advance PR600.
“It is our goal to find solutions that will ultimately help the millions of people living with inflammatory bowel disease and the Prometheus team has been a strong partner with a differentiated approach to help us exceed that goal,” said Roland Greinwald, Ph.D., Managing Director Medicine and Pharmaceutics, Dr. Falk Pharma.
Download Prometheus Biosciences' press release here: